Medexus Pharmaceuticals Inc.
MEDXF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -4.2% | 4.6% | 40.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 52.2% | 52.6% | 55.5% | 49.4% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 15.5% | 17.1% | 13.5% | 19.8% |
| Net Income | $0 | -$0 | $0 | -$0 |
| % Margin | 2.1% | -0.2% | 1.1% | -3.8% |
| EPS Diluted | 0.082 | -0.01 | 0.06 | -0.14 |
| % Growth | 962.1% | -115.8% | 142.9% | – |
| Operating Cash Flow | $0 | $0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | -$0 | -$0 |